Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 1:40 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 6,268 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid Clear all
Terminated Phase 3 Interventional Results available

CoQ10 and Prednisone in Non-Ambulatory DMD

NCT00308113
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Prednisone, Coenzyme Q10
Drug · Dietary Supplement
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
10 Years to 18 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Nov 2, 2026, 1:40 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NCT03817320
View directory record Official record
Conditions
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Interventions
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 2 Interventional Results available

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00474383
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, Glucocorticoid
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 2 Interventional Results available

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

NCT00822120
View directory record Official record
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
bleomycin sulfate, filgrastim, ABVD regimen, BEACOPP regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 60 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
423
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 4 Interventional Results available

Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)

NCT02237079
View directory record Official record
Conditions
Obesity, Glucose Homeostasis, Postmenopausal Symptoms
Interventions
Bazedoxifene/Conjugated Estrogens (BZA/CE), Placebo Oral Tablet
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
50 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Nov 2, 2026, 1:40 AM EST
Active, not recruiting Early Phase 1 Interventional

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

NCT04514029
View directory record Official record
Conditions
Lymphoma
Interventions
Simvastatin, Dexamethasone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 2 Interventional

SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00006002
View directory record Official record
Conditions
Prostate Cancer
Interventions
dexamethasone, semaxanib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Nov 2, 2026, 1:40 AM EST
Completed No phase listed Observational Results available

A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block

NCT02151487
View directory record Official record
Conditions
Upper Extremity Surgery
Interventions
Ropivacaine, Ropivacaine and dexamethasone, Ropivacaine and clonidine, Ropivacaine, dexamethasone and clonidine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Nov 2, 2026, 1:40 AM EST
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

NCT00929006
View directory record Official record
Conditions
Puberty, Hyperandrogenism
Interventions
Micronized progesterone suspension, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Bleeding With Extended Administration of an Oral Contraceptive

NCT00338052
View directory record Official record
Conditions
Contraception
Interventions
Norethindrone 1 mg / ethinyl estradiol 20 mcg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
25 Years to 40 Years · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Carmichael, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

NCT00140803
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Visudyne, Kenalog
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2007 · Synced Nov 2, 2026, 1:40 AM EST
Withdrawn Phase 4 Interventional

Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT02119273
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 3 Interventional

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00017602
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
oblimersen sodium, dexamethasone
Biological · Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Berkeley Heights, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 1 Interventional

Impact of Parathyroid Hormone (PTH) on Osseous Cavity

NCT00277706
View directory record Official record
Conditions
Bone Loss, Periodontitis
Interventions
Periodontal surgery, FORTEO, Placebo, Vitamin D and Calcium
Procedure · Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2009 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 1Phase 2 Interventional

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

NCT02575963
View directory record Official record
Conditions
AML
Interventions
Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only), Spironolactone
Drug · Biological
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 2 Interventional Results available

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

NCT00445887
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Levonorgestrel, Placebo
Other · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
30 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
66
States / cities
Duarte, California • Los Angeles, California • Orange, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Nov 2, 2026, 1:40 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

NCT04115306
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
PMD-026, fulvestrant
Drug
Lead sponsor
Phoenix Molecular Designs
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Gilbert, Arizona • Duarte, California • Irvine, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Male Hormones on Regional Fat Metabolism

NCT01160328
View directory record Official record
Conditions
Obesity
Interventions
Leuprolide, Testosterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 2 Interventional

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1

NCT06004830
View directory record Official record
Conditions
Alcohol Use Disorder, Hiv
Interventions
Spironolactone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Estetrol Monohydrate (E4) on QTc Interval

NCT04819906
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Estetrol 20 mg, Estetrol 100 mg, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 2 Interventional Results available

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

NCT03202628
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 2, 2026, 1:40 AM EST
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 2, 2026, 1:40 AM EST
Completed Phase 4 Interventional Results available

Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients

NCT03469271
View directory record Official record
Conditions
Cancer
Interventions
1,25 (OH)2 D3, Inspiratory isometric resistance training, Oral Placebo, Sham Inspiratory Isometric Resistance Training, Threshold Inspiratory Muscle Trainer (IMT)
Drug · Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Nov 2, 2026, 1:40 AM EST